棘白菌素耐药的近平滑念珠菌快速出现导致临床和微生物学失败。
Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure.
机构信息
University Health System, Department of Pharmacy, San Antonio, Texas, USA.
出版信息
Antimicrob Agents Chemother. 2013 Sep;57(9):4559-61. doi: 10.1128/AAC.01144-13. Epub 2013 Jul 1.
Abstract
We report a case of Candida glabrata candidemia that developed resistance to micafungin within 8 days of initiation of therapy in a patient without previous echinocandin exposure or other known risk factors for clinical or microbiological failure. Pre- and postresistant isolates were confirmed to be isogenic, and sequencing of hot spots known to confer echinocandin resistance revealed a phenylalanine deletion at codon 659 within FKS2.
摘要
我们报告了一例念珠菌属光滑念珠菌血症的病例，该患者在开始治疗后 8 天内对米卡芬净产生耐药性，此前没有接触过棘白菌素或其他已知的临床或微生物失败的危险因素。耐药前和耐药后的分离株被确认为同系物，对已知赋予棘白菌素耐药性的热点进行测序显示 FKS2 内 659 位密码子的苯丙氨酸缺失。
相似文献
1
Rapid emergence of echinocandin resistance in Candida glabrata resulting in clinical and microbiologic failure.
Antimicrob Agents Chemother. 2013 Sep;57(9):4559-61. doi: 10.1128/AAC.01144-13. Epub 2013 Jul 1.
2
Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata.
PLoS Pathog. 2012;8(5):e1002718. doi: 10.1371/journal.ppat.1002718. Epub 2012 May 17.
3
Antifungal drug susceptibility, molecular basis of resistance to echinocandins and molecular epidemiology of fluconazole resistance among clinical Candida glabrata isolates in Kuwait.
Sci Rep. 2020 Apr 10;10(1):6238. doi: 10.1038/s41598-020-63240-z.
4
Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.
Antimicrob Agents Chemother. 2014 Aug;58(8):4690-6. doi: 10.1128/AAC.03255-14. Epub 2014 Jun 2.
5
The presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.
Antimicrob Agents Chemother. 2012 Sep;56(9):4862-9. doi: 10.1128/AAC.00027-12. Epub 2012 Jul 2.
6
Spontaneous Mutational Frequency and Mutation Rates Vary by Echinocandin Agent against .
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01692-18. Print 2019 Jan.
7
Novel and modifications in a high-level echinocandin resistant clinical isolate of .
Emerg Microbes Infect. 2019;8(1):1619-1625. doi: 10.1080/22221751.2019.1684209.
8
Breakthrough candidemia due to multidrug-resistant Candida glabrata during prophylaxis with a low dose of micafungin.
Antimicrob Agents Chemother. 2014;58(4):2438-40. doi: 10.1128/AAC.02189-13. Epub 2014 Jan 27.
9
In Vitro Exposure to Increasing Micafungin Concentrations Easily Promotes Echinocandin Resistance in Candida glabrata Isolates.
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.01542-16. Print 2017 Feb.
10
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
Clin Infect Dis. 2013 Jun;56(12):1724-32. doi: 10.1093/cid/cit136. Epub 2013 Mar 13.
引用本文的文献
1
Leveraging synthetic genetic array screening to identify therapeutic targets and inhibitors for combatting azole resistance in .
Microbiol Spectr. 2025 Sep 2;13(9):e0252224. doi: 10.1128/spectrum.02522-24. Epub 2025 Aug 11.
2
Expression of 1,3-β-glucan synthase subunits in is regulated by the cell cycle and growth conditions and at both transcriptional and post-transcriptional levels.
Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0050025. doi: 10.1128/aac.00500-25. Epub 2025 Jun 17.
3
Current Epidemiology of Infection.
Clin Microbiol Newsl. 2014 Sep;36(17):131-136. doi: 10.1016/j.clinmicnews.2014.08.001.
4
Evolutionary dynamics in gut-colonizing Candida glabrata during caspofungin therapy: Emergence of clinically important mutations in sphingolipid biosynthesis.
PLoS Pathog. 2024 Sep 9;20(9):e1012521. doi: 10.1371/journal.ppat.1012521. eCollection 2024 Sep.
5
Initial micafungin treatment does not improve outcomes compared to fluconazole treatment in immunocompromised and critically ill patients with candidaemia.
J Antimicrob Chemother. 2024 Aug 1;79(8):1877-1884. doi: 10.1093/jac/dkae175.
6
Progress in the application of nanoparticles for the treatment of fungal infections: A review.
Mycology. 2023 Dec 8;15(1):1-16. doi: 10.1080/21501203.2023.2285764. eCollection 2024.
7
Macrophage internalization creates a multidrug-tolerant fungal persister reservoir and facilitates the emergence of drug resistance.
Nat Commun. 2023 Mar 2;14(1):1183. doi: 10.1038/s41467-023-36882-6.
8
Transcriptomics and Phenotyping Define Genetic Signatures Associated with Echinocandin Resistance in Candida auris.
mBio. 2022 Aug 30;13(4):e0079922. doi: 10.1128/mbio.00799-22. Epub 2022 Aug 15.
9
Clumping Morphology Influences Virulence Uncoupled from Echinocandin Resistance in Candida glabrata.
Microbiol Spectr. 2022 Feb 23;10(1):e0183721. doi: 10.1128/spectrum.01837-21. Epub 2022 Feb 2.
10
Case Report: Echinocandin-Resistance Mutants From Patient Following Radical Cystoprostatectomy Due to Muscle-Invasive Bladder Cancer.
Front Oncol. 2021 Dec 15;11:794235. doi: 10.3389/fonc.2021.794235. eCollection 2021.
本文引用的文献
1
Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure.
Antimicrob Agents Chemother. 2013 Aug;57(8):3528-35. doi: 10.1128/AAC.00136-13. Epub 2013 May 13.
2
Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
Clin Infect Dis. 2013 Jun;56(12):1724-32. doi: 10.1093/cid/cit136. Epub 2013 Mar 13.
3
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: adults with haematological malignancies and after haematopoietic stem cell transplantation (HCT).
Clin Microbiol Infect. 2012 Dec;18 Suppl 7:53-67. doi: 10.1111/1469-0691.12041.
4
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp.
Clin Microbiol Infect. 2012 Dec;18 Suppl 7:38-52. doi: 10.1111/1469-0691.12040.
5
ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients.
Clin Microbiol Infect. 2012 Dec;18 Suppl 7:19-37. doi: 10.1111/1469-0691.12039.
6
Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis: a patient-level quantitative review of randomized trials.
Clin Infect Dis. 2012 Apr;54(8):1110-22. doi: 10.1093/cid/cis021. Epub 2012 Mar 12.
7
Breakthrough invasive candidiasis in patients on micafungin.
J Clin Microbiol. 2010 Jul;48(7):2373-80. doi: 10.1128/JCM.02390-09. Epub 2010 Apr 26.
8
Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint.
Antimicrob Agents Chemother. 2009 Sep;53(9):3690-9. doi: 10.1128/AAC.00443-09. Epub 2009 Jun 22.
9
Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.
Clin Infect Dis. 2009 Mar 1;48(5):503-35. doi: 10.1086/596757.
10
Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.
Antimicrob Agents Chemother. 2008 Oct;52(10):3783-5. doi: 10.1128/AAC.00473-08. Epub 2008 Aug 1.
Zotero 插件